Completed PHASE3 INTERVENTIONAL 1-arm NCT00362479

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-Day Oral Contraceptive DR-1021

Sponsor: Duramed Research

Conditions Contraception

Interventions DR-1021

Updated 8 times since 2017 Last updated: Aug 20, 2013 Started: Aug 31, 2006 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Contraception, this trial is completed. The trial is conducted by Duramed Research and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jan 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duramed Research

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Arlington, United States , Atlanta, United States , Austin, United States , Aventura, United States , Boise, United States , Boynton Beach, United States , Bristol, United States , Brooksville, United States , Carmichael, United States and 67 more locations